Atogepant: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and NICE (England), among others, recommended or restricted atogepant, while AOTMIT (Poland), HAS (France) and PBAC (Australia) did not recommend it.
The record spans 3.2 years, opening at AWMSG (Wales) on 17 Mar 2023 and running to 30 Jun 2026.
ZIN (Netherlands) changed its position: recommended on 23 Oct 2024, restricted by 22 Oct 2025.
Every one of the eight highest-volume agencies in this archive has a record for atogepant.
The file is active: 19 of 19 records date from 2023 or later.
7 distinct indication wordings are recorded for atogepant by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 19 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess atogepant, on 17 Mar 2023; CHUIKYO (Japan) did not open a file until 8 Apr 2026 — a wide spread of 3.1 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed atogepant to a subgroup rather than accepting or refusing it outright, at NICE (England), SMC (Scotland) and TLV (Sweden) among others.
5 of the 13 agencies here assessed atogepant more than once, AWMSG (Wales) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
atogepant has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for atogepant reads 5 recommended, 4 restricted, 3 deferred to NICE and 3 not recommended, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 19 May 2026 | Acute treatment of migraine with or without aura in adults | excluded, NICE appraised | source |
| CHUIKYO (Japan) | 15 Apr 2026 | アクイプタ錠１０ｍｇ | listed on the NHI price list · 55 days after PMDA approval | source |
| AOTMIT (Poland) | 28 Oct 2025 | programu lekowego B.133. „Profilaktyczne leczenie chorych na migrenę przewlekła (ICD-10: G43) | not recommended | source |
| ZIN (Netherlands) | 22 Oct 2025 | Advies - uitbreiding vergoedingsvoorwaarden atogepant (Aquipta®) voor de behandeling van episodische migraine | conditions amended | source |
| G-BA (Germany) | 21 Aug 2025 | Aquipta — benefit assessment §35a | added benefit: not proven | source |
14 further decisions for atogepant, across 11 agencies, are not shown here. They include the most recent record on file, 30 Jun 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- galcanezumab — same ATC class N02C — Analgesics
- erenumab — same ATC class N02C — Analgesics
- fremanezumab — same ATC class N02C — Analgesics
- rimegepant — same ATC class N02C — Analgesics
- eptinezumab — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 19 decisions for atogepant from 13 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.